Comparison of estrogen receptor-α, progesterone receptor and calponin expression in gonadotrophin-releasing hormone agonist-sensitive and -resistant uterine fibroids
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveThis study was aimed to compare immunohistochemical expression of estrogen receptor (ER)-α, progesterone receptor (PR), and calponin in gonadotrophin-releasing hormone agonist (GnRH-a)-sensitive and -resistant uterine fibroids. MethodsWe collected data retrospectively. The sensitive group consisted of women who had reduction in uterine volume greater than 40% following GnRH-a treatment. Uterine volume was either reduced by less than 10%, or was increased in the resistant group. A tissue microarray was constructed using formalin-fixed, paraffin-embedded tissues, 31 and 26 patients for the sensitive and resistant groups, respectively. Tissue sections were immunostained with antibodies against ER-α, PR, and calponin. The intensity and area of the immunohistochemical reactions were evaluated using a semi-quantitative scoring system. The Mann-Whitney U-test, Fisher’s exact test, and Spearman’s rank correlation test were used for analysis of data. ResultsPR (P = 0.04) and calponin (P = 0.03) showed a significantly higher staining intensity in the resistant group than in the sensitive group. Both groups showed comparable expression of ER-α (P = 0.23). In correlation analysis between changes in uterine volume after GnRH-a therapy and clinicopathological factors, the immunohistochemical intensity of PR (P = 0.04) and calponin (P = 0.03) was significantly correlated with changes in uterine volume. ConclusionThis study shows that GnRH-a resistance of uterine fibroids is not related to ER-α content, but the expression of PR and calponin is related with GnRH-a resistance.
Abstract
ObjectiveThis study was aimed to compare immunohistochemical expression of estrogen receptor (ER)-α, progesterone receptor (PR), and calponin in gonadotrophin-releasing hormone agonist (GnRH-a)-sensitive and -resistant uterine fibroids. MethodsWe collected data retrospectively. The sensitive group consisted of women who had reduction in uterine volume greater than 40% following GnRH-a treatment. Uterine volume was either reduced by less than 10%, or was increased in the resistant group. A tissue microarray was constructed using formalin-fixed, paraffin-embedded tissues, 31 and 26 patients for the sensitive and resistant groups, respectively. Tissue sections were immunostained with antibodies against ER-α, PR, and calponin. The intensity and area of the immunohistochemical reactions were evaluated using a semi-quantitative scoring system. The Mann-Whitney U-test, Fisher’s exact test, and Spearman’s rank correlation test were used for analysis of data. ResultsPR (P = 0.04) and calponin (P = 0.03) showed a significantly higher staining intensity in the resistant group than in the sensitive group. Both groups showed comparable expression of ER-α (P = 0.23). In correlation analysis between changes in uterine volume after GnRH-a therapy and clinicopathological factors, the immunohistochemical intensity of PR (P = 0.04) and calponin (P = 0.03) was significantly correlated with changes in uterine volume. ConclusionThis study shows that GnRH-a resistance of uterine fibroids is not related to ER-α content, but the expression of PR and calponin is related with GnRH-a resistance.
참고문헌 (17)
- Wilson EA, "Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues", Obstet Gynecol, 55, pp.20~24 (1980)
- Tamaya T, "Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium", Acta Obstet Gynecol Scand, 64, pp.307~309 (1985)
- Vollenhoven BJ, "Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women", Clin Endocrinol (Oxf), 40, pp.537~544 (1994)
- Filicori M, "A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue", Am J Obstet Gynecol, 147, pp.726~727 (1983)
- Maheux R, "Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study", Am J Obstet Gynecol, 152, pp.1034~1038 (1985)
- Adamson GD, "Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists", Am J Obstet Gynecol, 166, pp.746~751 (1992)
- Watanabe Y, "Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women", Fertil Steril, 58, pp.66~71 (1992)
- Zhu XQ, "Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma", Gynecol Oncol, 92, pp.71~79 (2004)
- Thor AD, "Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism", J Natl Cancer Inst, 85, pp.176~177 (1993)
- Lethaby A, "Efficacy of preoperative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review", BJOG, 109, pp.1097~1108 (2002)
- Hong DG, "Analysis of factors affecting vaginal hysterectomy", Minim Invasive Ther Allied Technol, 18, pp.317~321 (2009)
- Nakayama M, "Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas", Pathol Int, 58, pp.268~274 (2008)
- Horiuchi A, "Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of alphasmooth muscle actin, calponin h1 and p27", Mol Hum Reprod, 5, pp.139~145 (1999)
- Cirkel U, "Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone. Analogue depot therapy", Acta Obstet Gynecol Scand, 73, pp.328~332 (1994)
- Reinsch RC, "The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study", Am J Obstet Gynecol, 170, pp.1623~1627 (1994)
- Harrison-Woolrych M, "Fibroid growth in response to high-dose progestogen", Fertil Steril, 64, pp.191~192 (1995)
- Millan Y, "Steroid receptors in canine and human female genital tract tumours with smooth muscle differentiation", J Comp Pathol, 136, pp.197~201 (2007)